Isochem owner buys Copperhead
New Jersey-based PMC Group International, a diversified manufacture of chemicals and pharmaceuticals, has acquired Cobra Investments Management from a consortium of previous owners. This includes Copperhead Chemical, which has a 350-hectare site at Tamaqua, Pennsylvania. Terms were not disclosed.
Group president Dr. Raj Chakrabarti said that Copperhead “will fit neatly and synergistically with our other pharmaceutical services and manufacturing companies”. As well as being the sole US manufacturer of nitroglycerin as a drug, Copperhead is a custom manufacturer of drug dosage forms, and makes explosives and propellants for the defence industry, preservatives and antimicrobials.
PMC owns French CDMO PMC-Isochem, which offers excipients and APIs, plus protein engineering, drug development and drug discovery services; and PMC YM-Pharma in India, which provides process development and pharmaceutical intermediate manufacturing services. Manufacturing and marketing synergies are also envisaged with PMC Ouvrie, which makes defoamers, surfactants and protective colloids for food and gneral industrial applications.